Our Research
SEMA4D
Vaccinex’s lead clinical programs are focused on inhibition of semaphorin 4D (SEMA4D), a novel target and an important biological effector whose expression is implicated in the progression of a number of neurological diseases and cancers.
Vaccinex’s mission is to deliver innovative therapies that improve the lives of patients and provide treatment solutions for critical unmet needs. Through deep understanding of science and pathology of disease, we are pioneering a differentiated approach to treating neurologic diseases and cancer with novel antibody therapeutics.Â
​
Our scientists actively contribute to the scientific community through peer-reviewed publications, scientific posters, and presentations at leading industry and academic conferences.
​